clofazimine has been researched along with Atypical Mycobacterial Infection, Disseminated in 35 studies
Clofazimine: A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619)
clofazimine : 3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mycobacterial osteomyelitis is rare, difficult to diagnose and treat, and may necessitate prolonged interruption of anti-leukemic therapy." | 5.62 | A child with acute myeloid leukemia complicated by calcaneal osteomyelitis due to Mycobacterium abscessus infection after induction chemotherapy successfully salvaged with bedaquiline and clofazimine. ( Chan, WY; Ha, SY; Ho, KW; Ho, PL; Lam, AY; Lau, TW; So, NL; To, KK, 2021) |
| "Clofazimine (CFZ), an old hydrophobic riminophenazine, has a wide range of antimycobacterial activity ranging from leprosy to nontuberculous mycobacterial diseases." | 5.05 | Clofazimine: an old drug for never-ending diseases. ( Besozzi, G; Biagio, AD; Canetti, D; Codecasa, L; Comelli, A; Diaw, MM; Gaiera, G; Giacomelli, A; Intini, E; Riccardi, N; Udwadia, Z, 2020) |
| "Clofazimine has been in clinical use for almost 40 years, but little is known of its mechanism of action." | 2.39 | Clofazimine: a review of its medical uses and mechanisms of action. ( Arbiser, JL; Moschella, SL, 1995) |
| " As an opportunistic pathogen with increasing antibiotics resistance, prolonged systemic dosing with multiple antibiotics remains the primary treatment paradigm." | 1.91 | Clofazimine Inhalation Suspension Demonstrates Promising Toxicokinetics in Canines for Treating Pulmonary Nontuberculous Mycobacteria Infection. ( Doyle-Eisele, M; Grant, M; Hittinger, M; Hofmann, T; Kuehl, P; Kunkel, M; Reed, M; Rotermund, K; Ufer, S, 2023) |
| "PBTZ169 appears to be a candidate for treating four common NTM infections." | 1.91 | Efficacy of PBTZ169 and pretomanid against Mycobacterium avium, ( Chen, X; Fu, L; Lu, Y; Qi, X; Wang, B; Wang, H; Zhang, W; Zheng, L, 2023) |
| "Clofazimine has been regarded as a promising agent for the treatment of nontuberculous mycobacteria pulmonary disease (NTM-PD)." | 1.62 | Minimal Inhibitory Concentration of Clofazimine Among Clinical Isolates of Nontuberculous Mycobacteria and Its Impact on Treatment Outcome. ( Kim, SA; Kim, TS; Kwak, N; Whang, J; Yang, JS; Yim, JJ, 2021) |
| "Mycobacterial osteomyelitis is rare, difficult to diagnose and treat, and may necessitate prolonged interruption of anti-leukemic therapy." | 1.62 | A child with acute myeloid leukemia complicated by calcaneal osteomyelitis due to Mycobacterium abscessus infection after induction chemotherapy successfully salvaged with bedaquiline and clofazimine. ( Chan, WY; Ha, SY; Ho, KW; Ho, PL; Lam, AY; Lau, TW; So, NL; To, KK, 2021) |
| "Oral clofazimine was added in cases of (1) M abscessus subspecies abscessus (here M abscessus) or (2) M abscessus subspecies massiliense (here M massiliense) with cavitary lesions." | 1.62 | Outcomes of Inhaled Amikacin-Containing Multidrug Regimens for Mycobacterium abscessus Pulmonary Disease. ( Daley, CL; Huh, HJ; Jeon, K; Jhun, BW; Kang, N; Kim, H; Koh, WJ; Kwon, OJ; Lee, NY, 2021) |
| "Clofazimine has excellent in vitro activity against M abscessus, but reports of its use, particularly in children, have been limited." | 1.56 | Safety and Tolerability of Clofazimine in a Cohort of Children With Odontogenic Mycobacterium abscessus Infection. ( Adler-Shohet, FC; Arrieta, A; Ashouri, N; Flores, MC; Nieves, D; Singh, J; Tran, MT, 2020) |
| "Clofazimine is an antimicrobial agent that has activity in vitro against mycobacteria." | 1.46 | Safety and Effectiveness of Clofazimine for Primary and Refractory Nontuberculous Mycobacterial Infection. ( Daley, CL; Levin, A; Martiniano, SL; Nick, JA; Sagel, SD; Wagner, BD, 2017) |
| "Clofazimine was highly efficacious against these RGM." | 1.36 | High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria. ( Chen, JH; Hu, ST; Lin, CF; Shen, GH; Wu, BD; Wu, KM, 2010) |
| "Four patients with acquired immunodeficiency syndrome with bacillemia from Mycobacterium avium-intracellulare presented with early pathologic clues of a disseminated mycobacterial infection." | 1.27 | Clues to the early diagnosis of Mycobacterium avium-intracellulare infection in patients with acquired immunodeficiency syndrome. ( Polis, MA; Tuazon, CU, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.71) | 18.7374 |
| 1990's | 4 (11.43) | 18.2507 |
| 2000's | 4 (11.43) | 29.6817 |
| 2010's | 10 (28.57) | 24.3611 |
| 2020's | 15 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Cameron, LH | 1 |
| Peloquin, CA | 1 |
| Hiatt, P | 1 |
| Mann, M | 1 |
| Starke, JR | 1 |
| Faircloth, J | 1 |
| McNeil, JC | 1 |
| Patel, A | 1 |
| Ruiz, F | 1 |
| Sorayah, R | 1 |
| Moraski, GC | 1 |
| Barkan, D | 1 |
| Pethe, K | 1 |
| Schulthess, B | 1 |
| Akdoğan Kittana, FN | 1 |
| Hömke, R | 1 |
| Sander, P | 1 |
| Kunkel, M | 1 |
| Doyle-Eisele, M | 1 |
| Kuehl, P | 1 |
| Rotermund, K | 1 |
| Hittinger, M | 1 |
| Ufer, S | 2 |
| Reed, M | 1 |
| Grant, M | 1 |
| Hofmann, T | 2 |
| Zheng, L | 1 |
| Qi, X | 1 |
| Zhang, W | 1 |
| Wang, H | 1 |
| Fu, L | 1 |
| Wang, B | 1 |
| Chen, X | 2 |
| Lu, Y | 1 |
| Siegel, SAR | 1 |
| Griffith, DE | 1 |
| Philley, JV | 1 |
| Brown-Elliott, BA | 1 |
| Brunton, AE | 1 |
| Sullivan, PE | 1 |
| Fuss, C | 1 |
| Strnad, L | 1 |
| Wallace, RJ | 1 |
| Winthrop, KL | 1 |
| Sürücüoğlu, S | 1 |
| Özkütük, N | 1 |
| Gazi, H | 1 |
| Çavuşoğlu, C | 1 |
| Thomson, R | 1 |
| Radigan, A | 1 |
| Jevert-Eichorn, S | 1 |
| van Wijk, F | 1 |
| Waterval, J | 1 |
| van Aerde, K | 1 |
| Henriet, SSV | 1 |
| Meijer, FJA | 1 |
| Borra, LC | 1 |
| Aarnoutse, RE | 1 |
| van Ingen, J | 3 |
| Pinapala, A | 1 |
| Koh, LJ | 1 |
| Ng, KH | 1 |
| Tambyah, PA | 1 |
| Yap, HK | 1 |
| Riccardi, N | 1 |
| Giacomelli, A | 1 |
| Canetti, D | 1 |
| Comelli, A | 1 |
| Intini, E | 1 |
| Gaiera, G | 1 |
| Diaw, MM | 1 |
| Udwadia, Z | 1 |
| Besozzi, G | 1 |
| Codecasa, L | 1 |
| Biagio, AD | 1 |
| Kwak, N | 1 |
| Whang, J | 1 |
| Yang, JS | 1 |
| Kim, TS | 1 |
| Kim, SA | 1 |
| Yim, JJ | 1 |
| Chan, WY | 1 |
| Ho, PL | 1 |
| To, KK | 1 |
| Lam, AY | 1 |
| Ho, KW | 1 |
| Lau, TW | 1 |
| So, NL | 1 |
| Ha, SY | 1 |
| Flores-Suárez, LF | 1 |
| Fernández-Sánchez, M | 1 |
| Ahumada-Topete, VH | 1 |
| Rodríguez, M | 1 |
| Charli-Joseph, Y | 1 |
| Kang, N | 1 |
| Jeon, K | 1 |
| Kim, H | 1 |
| Kwon, OJ | 1 |
| Huh, HJ | 1 |
| Lee, NY | 1 |
| Daley, CL | 2 |
| Koh, WJ | 1 |
| Jhun, BW | 1 |
| Aksamit, TR | 1 |
| Marras, TK | 1 |
| Martiniano, SL | 1 |
| Wagner, BD | 1 |
| Levin, A | 1 |
| Nick, JA | 1 |
| Sagel, SD | 1 |
| Yoon, HY | 1 |
| Jo, KW | 1 |
| Nam, GB | 1 |
| Shim, TS | 1 |
| Ruth, MM | 1 |
| Zheng, S | 1 |
| Lee, SFK | 1 |
| Laughon, BE | 1 |
| McHugh, TD | 1 |
| Lipman, M | 1 |
| Banaschewski, B | 1 |
| Verma, D | 1 |
| Pennings, LJ | 1 |
| Zimmerman, M | 1 |
| Ye, Q | 1 |
| Gadawa, J | 1 |
| Dartois, V | 1 |
| Ordway, D | 1 |
| Stapleton, K | 1 |
| Adler-Shohet, FC | 1 |
| Singh, J | 1 |
| Nieves, D | 1 |
| Ashouri, N | 1 |
| Tran, MT | 1 |
| Flores, MC | 1 |
| Arrieta, A | 1 |
| Shen, GH | 1 |
| Wu, BD | 1 |
| Hu, ST | 1 |
| Lin, CF | 1 |
| Wu, KM | 1 |
| Chen, JH | 1 |
| Kullavanijaya, P | 1 |
| Rattana-Apiromyakij, N | 1 |
| Sukonthapirom-Napattalung, P | 1 |
| Sirimachand, S | 1 |
| Duangdeeden, I | 1 |
| Thangaraj, HS | 1 |
| Phillips, RO | 1 |
| Evans, MR | 1 |
| Wansbrough-Jones, MH | 1 |
| da Silva Telles, MA | 1 |
| Chimara, E | 1 |
| Ferrazoli, L | 1 |
| Riley, LW | 1 |
| Nenoff, P | 1 |
| Uhlemann, R | 1 |
| Grünewald, T | 1 |
| Nenning, H | 1 |
| Grunewald, S | 1 |
| Paasch, U | 1 |
| Finet, JF | 1 |
| Similowski, T | 1 |
| Derenne, JP | 1 |
| Le Charpentier, Y | 1 |
| Arbiser, JL | 1 |
| Moschella, SL | 1 |
| Prantera, C | 1 |
| Kohn, A | 1 |
| Mangiarotti, R | 1 |
| Andreoli, A | 1 |
| Luzi, C | 1 |
| Zaugg, M | 1 |
| Salfinger, M | 1 |
| Opravil, M | 1 |
| Lüthy, R | 1 |
| Masur, H | 1 |
| Tuazon, C | 1 |
| Gill, V | 1 |
| Grimes, G | 1 |
| Baird, B | 1 |
| Fauci, AS | 1 |
| Lane, HC | 1 |
| Polis, MA | 1 |
| Tuazon, CU | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Characteristics of Patients With Nontuberculosis Mycobacteria in Korean Population[NCT01616745] | 500 participants (Anticipated) | Observational | 2011-07-31 | Recruiting | |||
| Identification of Host Susceptibility Factors and Development of Biomarkers for Diagnosis, Prognosis and Treatment of Nontuberculous Mycobacterial Lung Disease[NCT00970801] | 300 participants (Anticipated) | Observational | 2008-01-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for clofazimine and Atypical Mycobacterial Infection, Disseminated
| Article | Year |
|---|---|
Clofazimine: an old drug for never-ending diseases.
Topics: Animals; Anti-Bacterial Agents; Clofazimine; Drug Resistance, Bacterial; Humans; Leprosy; Mycobacter | 2020 |
New drugs to treat difficult tuberculous and nontuberculous mycobacterial pulmonary disease.
Topics: Amikacin; Anti-Bacterial Agents; Clofazimine; Diarylquinolines; Extensively Drug-Resistant Tuberculo | 2019 |
Emerging aspects of Buruli ulcer.
Topics: Animals; Clofazimine; Drug Resistance, Bacterial; Humans; Leprostatic Agents; Mycobacterium Infectio | 2003 |
Clofazimine: a review of its medical uses and mechanisms of action.
Topics: Clofazimine; DNA, Bacterial; Humans; Intercalating Agents; Mycobacterium Infections; Mycobacterium I | 1995 |
Extrapulmonary and disseminated infections due to Mycobacterium malmoense: case report and review.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antitubercular Agents; Clofazim | 1993 |
1 trial available for clofazimine and Atypical Mycobacterial Infection, Disseminated
| Article | Year |
|---|---|
Antimycobacterial therapy in Crohn's disease: results of a controlled, double-blind trial with a multiple antibiotic regimen.
Topics: Adult; Anti-Bacterial Agents; Antitubercular Agents; Clofazimine; Crohn Disease; Dapsone; Double-Bli | 1994 |
29 other studies available for clofazimine and Atypical Mycobacterial Infection, Disseminated
| Article | Year |
|---|---|
Administration and monitoring of clofazimine for NTM infections in children with and without cystic fibrosis.
Topics: Child; Clofazimine; Cystic Fibrosis; Humans; Mycobacterium Infections, Nontuberculous; Nontuberculou | 2022 |
The QcrB Inhibitors TB47 and Telacebec Do Not Potentiate the Activity of Clofazimine in Mycobacterium abscessus.
Topics: Anti-Bacterial Agents; Antitubercular Agents; Clofazimine; Humans; Imidazoles; Microbial Sensitivity | 2021 |
Topics: Anti-Bacterial Agents; Antitubercular Agents; Clofazimine; Diarylquinolines; Humans; Microbial Sensi | 2022 |
Clofazimine Inhalation Suspension Demonstrates Promising Toxicokinetics in Canines for Treating Pulmonary Nontuberculous Mycobacteria Infection.
Topics: Animals; Anti-Bacterial Agents; Clofazimine; Dogs; Female; Lung; Male; Mycobacterium Infections, Non | 2023 |
Efficacy of PBTZ169 and pretomanid against Mycobacterium avium,
Topics: Animals; Anti-Bacterial Agents; Clofazimine; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; | 2023 |
Open-Label Trial of Amikacin Liposome Inhalation Suspension in Mycobacterium abscessus Lung Disease.
Topics: Amikacin; Anti-Bacterial Agents; Azithromycin; Clofazimine; Cystic Fibrosis; Drug Resistance, Bacter | 2023 |
[In vitro Activity of Rifabutin and Clofazimine to Macrolide-Resistant Mycobacterium abscessus Complex Clinical Isolates].
Topics: Aminoglycosides; Anti-Bacterial Agents; Clarithromycin; Clofazimine; Drug Resistance, Bacterial; Hum | 2023 |
Inhaled therapies for NTM disease - The way forward?
Topics: Aerosols; Clofazimine; Cystic Fibrosis; Humans; Mycobacterium Infections, Nontuberculous; Nontubercu | 2019 |
Rare case of pacemaker infection with
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Arrhythmias, Cardiac; Cefoxitin; Clarithromy | 2019 |
Successful Systemic and Topical Treatment of Mycobacterium abscessus Otomastoiditis.
Topics: Administration, Oral; Adolescent; Anti-Bacterial Agents; Azithromycin; Child; Clofazimine; Combined | 2019 |
Clofazimine in
Topics: Adult; Child; Clofazimine; Drug Therapy, Combination; Female; Humans; Leprostatic Agents; Mycobacter | 2021 |
Minimal Inhibitory Concentration of Clofazimine Among Clinical Isolates of Nontuberculous Mycobacteria and Its Impact on Treatment Outcome.
Topics: Aged; Clofazimine; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Mycobacterium Inf | 2021 |
A child with acute myeloid leukemia complicated by calcaneal osteomyelitis due to Mycobacterium abscessus infection after induction chemotherapy successfully salvaged with bedaquiline and clofazimine.
Topics: Anti-Bacterial Agents; Child, Preschool; Clofazimine; Combined Modality Therapy; Diarylquinolines; D | 2021 |
After all, still a magnificent impersonator.
Topics: Adult; Biopsy; Clofazimine; Diagnostic Errors; Female; Humans; Leprostatic Agents; Mycobacterium; My | 2021 |
Outcomes of Inhaled Amikacin-Containing Multidrug Regimens for Mycobacterium abscessus Pulmonary Disease.
Topics: Administration, Inhalation; Aged; Amikacin; Anti-Bacterial Agents; Azithromycin; Clofazimine; Drug T | 2021 |
Clofazimine Drug Susceptibility Testing for Nontuberculous Mycobacteria: A Call to Arms.
Topics: Anti-Bacterial Agents; Clofazimine; Humans; Microbial Sensitivity Tests; Mycobacterium Infections, N | 2021 |
Safety and Effectiveness of Clofazimine for Primary and Refractory Nontuberculous Mycobacterial Infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Child; Clofazimine; Dose-Respo | 2017 |
Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Azithromycin; Child; Clarithromyc | 2017 |
New insights in the treatment of nontuberculous mycobacterial pulmonary disease.
Topics: Anti-Bacterial Agents; Clofazimine; Humans; Mycobacterium Infections, Nontuberculous; Nontuberculous | 2017 |
Nodular skin lesion secondary to Mycobacterium abscessus tenosynovitis.
Topics: Aged; Clarithromycin; Clofazimine; Debridement; Female; Fingers; Humans; Mycobacterium abscessus; My | 2018 |
Clofazimine inhalation suspension for the aerosol treatment of pulmonary nontuberculous mycobacterial infections.
Topics: Administration, Inhalation; Aerosols; Animals; Anti-Bacterial Agents; Biological Availability; Clofa | 2019 |
Safety and Tolerability of Clofazimine in a Cohort of Children With Odontogenic Mycobacterium abscessus Infection.
Topics: California; Child; Child, Preschool; Clofazimine; Cross Infection; Dental Offices; Disease Outbreaks | 2020 |
High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria.
Topics: Amikacin; Anti-Bacterial Agents; Clofazimine; Drug Synergism; Humans; Microbial Sensitivity Tests; M | 2010 |
Disseminated Mycobacterium chelonae cutaneous infection: recalcitrant to combined antibiotic therapy.
Topics: Adult; Anti-Bacterial Agents; Clarithromycin; Clofazimine; Cryotherapy; Drug Resistance; Drug Therap | 2003 |
Mycobacterium kansasii: antibiotic susceptibility and PCR-restriction analysis of clinical isolates.
Topics: Amikacin; Anti-Bacterial Agents; Brazil; Ciprofloxacin; Clarithromycin; Clofazimine; Cycloserine; DN | 2005 |
[Atypical mycobacteriosis of the skin caused by Mycobacterium abscessus in an immunocompetent woman].
Topics: Antitubercular Agents; Biopsy; Buruli Ulcer; Clofazimine; Drug Therapy, Combination; Female; Follow- | 2007 |
[Reversible pulmonary overload with clofazimine (Lamprene) in HIV-positive subjects].
Topics: AIDS-Related Opportunistic Infections; Bronchoalveolar Lavage Fluid; Clofazimine; HIV Seropositivity | 1995 |
Effect of combined clofazimine and ansamycin therapy on Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Amikacin; Anti-Bacterial Agents; Ciprofloxacin; Clofazimine; Cyc | 1987 |
Clues to the early diagnosis of Mycobacterium avium-intracellulare infection in patients with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Amikacin; Anti-Bacterial Agents; Clofazimine; Female; Hum | 1985 |